Botulinum toxin type A therapy for cervical dystonia

Area of Science:

• Neurology
• Pharmacology

Background:

• Cervical dystonia is a disabling movement disorder causing involuntary head posturing.
• Botulinum toxin type A (BtA) is a first-line therapy for cervical dystonia.

Purpose of the Study:

• To compare the efficacy and safety of botulinum toxin type A (BtA) versus placebo in cervical dystonia patients.
• To assess the tolerability of BtA treatment for cervical dystonia.

Main Methods:

• Systematic review and meta-analysis of randomized, placebo-controlled trials (RCTs).
• Searched multiple databases up to October 2016 for relevant studies.
• Included eight RCTs with 1010 participants, assessing primary outcomes of impairment and adverse events.

Main Results:

• BtA significantly improved cervical dystonia impairment (8.06 points reduction on TWSTRS) and pain at week 4 compared to placebo.
• Participants and clinicians reported subjective improvement, with no difference in adverse event-related withdrawals.
• Adverse events, including dysphagia and diffuse weakness, were more common with BtA treatment.

Conclusions:

• Single-session BtA treatment effectively reduces cervical dystonia severity, disability, and pain with moderate certainty of evidence.
• BtA is generally well-tolerated but increases the risk of adverse events like dysphagia and weakness.
• Further research is needed on repeated BtA cycles, optimal dosing, and long-term effects.